Day 1:Friday 4 February2022 Day 2:Saturday 5 February2020 Session I: Neuroendocrine Tumours Moderators: Faisal Albadainah View Details 9:00-9:20 Overview of NET View Details 9:20-9:40 Liver directed therapy in metastatic NET: benefits and risks View Details 9:40-10:00 Speaker: Role of nuclear medicine in NET: diagnosis and treatment View Details 10:00-10:20 Discussion View Details Session II: GI cancers Panel: Ali Aljubran, Emad Tashkandi, Mohamed Alqarni, Kanaan Alshemari, Mervat Mahrous, Khalid Alsaleh, Abderlrahim Shanqeeti View Details 10:20-11:00 MSI-H CRC -Do we need TMB assessment as well? -Immunetherapy with extensive visceral metastasis -What to give after failure of 1st line immunotherapy? -Locally advancer MSI-H CRC: what to give as an adjuvant therapy? Moderator: Mohamed Alqani View Details 11:00-11:40 Pancreatico-biliary cancers -Neoadjuvant therapy in resectable pancreatic cancer Duration of neoadjuvant chemotherapy Role of chemoradiotherapy Molecular tests in pancreaticobiliary cancer Moderator: Khalid Alsaleh View Details Session III: GI cancers Panel: Shouki Bazarbashi, Mohamed Alghamdi, Hani Elkhatib, Abdullah Alsharm, Fahed Ibn Shamsa, Waleed Selwi, Samah Alraheli View Details 14:00-14:40 Rectal cancer -Organ preservation in T1/T2 rectal cancer -Watch and wait in rectal cancer -Induction vs consolidation chemotherapy -Adjuvant chemotherapy:Yes or no Moderator: Mohamed Alghamdi View Details 14:40-15:20 GI cancer with Peritoneal carcinomatosis -HIPEC in advanced CRC -Chemotherapy component with HIPEC -Role of perioperative chemotherapy with CRS/HIPEC -HIPEC in gastric cancer Moderator: Abdullah Alsharm View Details 15:20-16:00 1st line metastatic CRC -Anti-EGFR with triplet -HER2 test before 1st line antiEGFR/Anti-EGFR with BRAF mutation -Doublet vs triplet in V600E BRAF mutation Moderator: Waleed Selwi View Details Session IV: Hepatobiliary Tumours Moderators: Marwan Al-Hejaili - Abdelaziz Tashkandi View Details 16:00-16:20 Cholangiocarcinoma treatment approaches of intrahepatic vs extrahepatic?? View Details 16:20-16:40 Periampullary carcinoma: optimal therapeutic management View Details 16:40-17:00 Role of antiviral therapy in patients with HCC View Details 17:00-17:20 Discussion View Details Session I: Early Breast Cancer Panel: Panel: Meteeb Alfohaidi, om Alkhair Aboelkhair, Adher Alsayed, Abdullah Alzahrani, Ahmed Alshehri, Jamal Zekri, Ahmed Alwabari, Ahmed Zeeneldin View Details 9:00-9:40 Adjuvant therapy in HER2-positive breast cancer trastuzumab 6 vs 12 months role of pertuzumab/niratinib Moderator: Om Alkhair Aboelkhair View Details 9:40 –10:20 Adjuvant hormonal therapy what is the optimal duration, duration of LHRH-analougues Lobular breast cancer N1 disease/molecular tools Moderator: Abdullah Alzahrani View Details 10:20-11:00 Triple negative breast cancer (Non-metastatic): Neoadjuvant immunetherapy/ platinum Postneoadjuvant therapy, PARPi in BRCA mutant Moderator: Ahmed Alwabari View Details 11:00-11:20 Break View Details Session II: Advanced breast cancer Panel: Aboelkhair Algahami, Ahmed Alrefaei, Shereef Elsamany, Abdullah Altwergi, Shadi Khayat, Essam Murshid, Atlal Abusanad, Nedal Bukhari View Details 11:20-12:00 HR-positive/HER2-negative breast cancer OS with CDK4-6 inhibitors: impact on treatment selection Alpelisib vs. everolimus in 2nd line Early progression after CDK4-6i: chemotherapy vs hormonal therapy Visceral crisis: duration of chemotherapy, role of maintenance hormonal therapy? Moderator: Ahmed Alrefaei View Details 12:00-12:40 Advanced HER2-positive breast cancer Position of ADC Can we use ADC after another ADC treatment sequence Hormonal therapy+antiHER2 in 1st line Moderator: Abdullah Altwergi View Details 12:40-13:20 Triple negative breast cancer Platinum vs PARPi/ can we use one after the other? can we use PARPi beyond BRCA1/2 mutations PARPi in1st line or later lines Immune therapy: Pembro vs atezolizumab in 1st line Can we use immunetherapy in 2nd line after chemotherapy /PARPi Moderator: Essam Murshid View Details 13:20-14:30 Prayer &Lunch View Details Session IV Hematological malignancies View Details Session 1 (Plasma Cell Disorders) Khalofa Alghamdi - Ashraf Warsi View Details 14:30-15:00 Therapy for AL amyloidosis View Details 15:00-15:30 Smoldering myeloma debates View Details 15:30-15:45 Q/A View Details 15:45-16:00 Coffee break View Details Session 2 (Acute Leukemia) Manal alsaggaf View Details 16:00-16:30 Updated Management of ph-like ALL View Details 16:30-17:00 Refining the role of Allo-BMT in ALL View Details 17:00-17:30 Challenges in invasive fungal infection View Details 17:30-17:45 Q/A View Details 17:45-17:50 Closing remarks View Details